The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a double blinded two-arm randomized case-only interventional trial. A total of 60
patients who are to receive Paclitaxel to be included and allocated in two groups. The
protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo
University.
All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine.
The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets
(Zimmerman et al., 2016).
The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)